SuperQuick® Cytochrome P450 2C19 (CYP2C19) Inhibitor Screening Kit

DMK-YS008

The oxidation of neutral or slightly basic lipophilic compounds with 2-3 hydrogen bound donor/acceptor sites is catalyzed by CYP2C19, which is primarily expressed in the liver and intestinal organs. CYP2C19 subfamily isoforms play a role in the metabolism of roughly 20% of routinely prescribed small molecule medicines. Clinical drug-drug interactions involving a wide range of prescribed drugs, including proton pump inhibitors, antiplatelet agents, and anticonvulsants, have been linked to the human CYP2C19 gene polymorphisms. Furthermore, CYP2C19 inhibition or allelic impairment can diminish therapeutic efficacy for medicines whose pharmacological activity requires metabolism from the prodrug form.Creative Bioarray's CYP2C19 Inhibitor Screening Kit provides rapid screening of compound-CYP2C19 interactions in a high-throughput fluorescent assay.

Perform rapid, high-throughput screening and characterization of compound interactions with CYP2C19.
Predict the adverse drug interaction potential and bioavailability of compounds metabolized by CYP2C19.

Simple and ready to use;
Rapid and high-throughput;
Hight sensitive.

Chemical compounds

CYP2C19 Assay Buffer;
3-CHC Standard;
CYP2C19Inhibitor ((+)-N-3-benzylnirvanol);
NADPH Generating System(100X);
β-NADP+Stock (100X);
CYP2C19 Substrate;
Recombinant Human CYP2C20.

100 assys

Strore at -20℃.

Gel Pack

If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no. If your paper has been published, please click here to submit the PubMed ID of your paper to get a coupon.